0000950170-25-074328.txt : 20250519 0000950170-25-074328.hdr.sgml : 20250519 20250519160534 ACCESSION NUMBER: 0000950170-25-074328 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250515 FILED AS OF DATE: 20250519 DATE AS OF CHANGE: 20250519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Teresa L. CENTRAL INDEX KEY: 0001814656 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 25963896 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: SUITE 1750 CITY: HOUSTON STATE: TX ZIP: 77098 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 ownership.xml 4 X0508 4 2025-05-15 0001609809 Seres Therapeutics, Inc. MCRB 0001814656 Young Teresa L. C/O SERES THERAPEUTICS, INC. 101 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 false true false false See Remarks true Common Stock 2025-05-15 4 M false 133 A 5009 D Common Stock 2025-05-15 4 M false 98 A 5107 D Common Stock 2025-05-16 4 S false 63 7.28 D 5044 D Restricted Stock Units 2025-05-15 4 M false 133 0 D Common Stock 133 929 D Restricted Stock Units 2025-05-15 4 M false 98 0 D Common Stock 98 1073 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Reflects a 1-for-20 reverse stock split effected on April 21, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. EVP, Chief Commercial & Strategy Officer /s/ Thomas J. DesRosier, attorney-in-fact for Teresa L. Young 2025-05-19